PCAT6 and neoplasm: The modification of PCAT6 with m6A determine the upregulation of PCAT6 in bone metastasis‐positive prostate cancer, the interaction with IGF2BP2 to stabilize IGF1R mRNA, the upregulation of IGF1R expression, and the promotion of PCa cell invasion, migration, tumour growth and bone metastasis formation (63).